According to its latest SEC Form 13F filing, Alpha Cubed Investments LLC boosted its stake in UnitedHealth Group by 250.5% during the third quarter, acquiring an additional 89,105 shares to bring its total to 124,682. This position represents approximately 1.5% of Alpha Cubed’s portfolio and ranks as its 18th largest holding. At quarter end, the firm’s UnitedHealth Group shares were valued at $43.05 million. Other boutique managers—including LFA Lugano Financial Advisors SA, Sagard Holdings Management Inc., Islay Capital Management LLC, Cloud Capital Management LLC, and Grey Fox Wealth Advisors LLC—initiated small positions during the second and third quarters, further underscoring institutional interest, with hedge funds and similar investors now controlling nearly 88% of the company’s float.

Equity research firms have recently revisited their outlook on UnitedHealth Group. Zacks Research upgraded the company from a “strong sell” to a “hold,” while JPMorgan Chase & Co. raised its price target by over 35% and maintained an “overweight” rating. Piper Sandler and KeyCorp both affirmed their overweight views, and Morgan Stanley issued a modest downward adjustment to its target while sustaining its bullish stance. Overall, out of 29 analysts covering the stock, 18 recommend buying, 9 advise holding, and 2 suggest selling. The consensus view across Wall Street equates to a Moderate Buy rating.

In its fourth-quarter report, UnitedHealth Group delivered adjusted earnings per share of $2.11, narrowly surpassing consensus by two cents, and generated quarterly revenue of $113.22 billion, up 12.3% year-over-year but slightly below analyst projections. The company achieved a return on equity of 14.8% and a net margin of 2.7%. Management set 2026 EPS guidance at approximately 17.75, reflecting expectations for margin recovery driven by cost synergies in Optum and disciplined benefit-cost management in UnitedHealthcare. Analysts forecast full-year earnings of roughly 29.5 per share.

UnitedHealth Group declared a quarterly dividend of 2.21 per share, payable to shareholders of record as of December 8, resulting in an annualized payout of 8.84 and a yield near 3.0%. The company’s current payout ratio stands at 67.0%, reflecting management’s commitment to returning capital while retaining flexibility for strategic investments in care delivery and technology initiatives.